NCT06431919View on ClinicalTrials.gov

Carvedilol + Simvastatin vs. Carvedilol Alone for Cirrhosis and Cirrhotic Cardiomyopathy and Impact on Hepatic Decompensation and Survival

NARecruitingINTERVENTIONAL
Enrollment

260

Participants

Timeline

Start Date

June 10, 2025

Primary Completion Date

January 31, 2028

Study Completion Date

February 29, 2028

Conditions
Decompensated CirrhosisCirrhotic CardiomyopathyCirrhosis, LiverLeft Ventricular Diastolic DysfunctionAcute Kidney Injury
Interventions
DRUG

Simvastatin 20mg

Simvastatin fixed dose of 20 mg per day

DRUG

Carvedilol 3.125 mg

Carvedilol: Starting dose of 3.125 mg twice daily targeted upwards q 7 days to achieve target heart rate

Trial Locations (1)

160012

RECRUITING

PGIMER, Department of Hepatology, Chandigarh

All Listed Sponsors
collaborator

Indian Council of Medical Research

OTHER_GOV

lead

Post Graduate Institute of Medical Education and Research, Chandigarh

OTHER

NCT06431919 - Carvedilol + Simvastatin vs. Carvedilol Alone for Cirrhosis and Cirrhotic Cardiomyopathy and Impact on Hepatic Decompensation and Survival | Biotech Hunter | Biotech Hunter